Register for free to listen to this article
Listen with Speechify
0:00
2:00
ZURICH, Switzerland—Immunomedics Inc. and Nycomed GmbH recently announced a license and collaboration agreement providing Nycomed a worldwide license to develop, manufacture and commercialize veltuzumab, Immunomedics' humanized anti-CD20 antibody in a subcutaneous formulation for the treatment of all non-cancer indications.

Under the terms of the deal, Immunomedics will receive a non-refundable initial cash payment of $40 million, subject to applicable Hart-Scott-Rodino Act approval, and could potentially earn milestone payments of up to $580 million upon completion of certain clinical, regulatory, and sales-based milestones. It also will receive escalating double-digit royalties on sales of veltuzumab for the indications.

"Nycomed is the ideal partner for veltuzumab," says Cynthia L. Sullivan, president and CEO of Immunomedics. "We believe their new research and development strategy that focuses on target areas outside of the field of oncology means that Nycomed will vigorously develop the full potential of veltuzumab in the field of autoimmune and inflammatory diseases."

Nycomed will develop veltuzumab in rheumatoid arthritis (RA) as the primary indication. Anti-CD20 antibodies are considered to be a growing segments within the RA market and offer additional potential by extending into other autoimmune and inflammatory diseases. The agreement also provides Immunomedics with an option to co-promote veltuzumab for immune thrombocytopenic purpura (ITP), an autoimmune disease treated by the same physician specialtist who treats blood cancers such as non-Hodgkin's lymphoma.

If Immunomedics exercises its option, it will have sole responsibility for sales calls for ITP in the United States. Profits from these sales will be shared based on a pre-arranged percentage allocation.

"This alliance with Immuno-medics is a significant step for Nycomed to extend its network with leading biopharmaceutical companies. Nycomed strengthens its clinical pipeline and veltuzumab offers an excellent strategic fit with Nycomed's other programs in the field of autoimmune and inflammatory diseases," says Hakan Bjorklund, Nycomed's CEO. "Within the growing market of anti-CD20s in the autoimmune area, we believe that veltuzumab differentiates and can offer significant medical benefit through its subcutaneous application route." DDN

Related Topics

Published In

Volume 4 - Issue 8 | August 2008

August 2008

August 2008 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue